Vaccitech plc (VACC): Price and Financial Metrics
VACC Price/Volume Stats
| Current price | $2.31 | 52-week high | $7.45 |
| Prev. close | $2.43 | 52-week low | $2.02 |
| Day low | $2.31 | Volume | 7,481 |
| Day high | $2.47 | Avg. volume | 50,256 |
| 50-day MA | $2.38 | Dividend yield | N/A |
| 200-day MA | $2.81 | Market Cap | 88.59M |
VACC Stock Price Chart Interactive Chart >
VACC Stock Summary
- VACC's went public 2.07 years ago, making it older than merely 6.82% of listed US stocks we're tracking.
- Equity multiplier, or assets relative to shareholders' equity, comes in at 1.12 for VACCITECH PLC; that's greater than it is for merely 10.03% of US stocks.
- As for revenue growth, note that VACC's revenue has grown 100.07% over the past 12 months; that beats the revenue growth of 93.76% of US companies in our set.
- Stocks that are quantitatively similar to VACC, based on their financial statements, market capitalization, and price volatility, are ONCT, ENTA, AEVA, ALGS, and RCUS.
- VACC's SEC filings can be seen here. And to visit VACCITECH PLC's official web site, go to www.vaccitech.co.uk.
VACC Valuation Summary
- VACC's price/earnings ratio is -6.2; this is 125.73% lower than that of the median Healthcare stock.
- Over the past 25 months, VACC's price/earnings ratio has gone up 20.9.
Below are key valuation metrics over time for VACC.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| VACC | 2023-05-23 | 3.2 | 0.4 | -6.2 | 4.3 |
| VACC | 2023-05-22 | 3.2 | 0.4 | -6.2 | 4.3 |
| VACC | 2023-05-19 | 3.1 | 0.4 | -6.1 | 4.4 |
| VACC | 2023-05-18 | 3.1 | 0.4 | -6.1 | 4.4 |
| VACC | 2023-05-17 | 3.0 | 0.4 | -5.9 | 4.6 |
| VACC | 2023-05-16 | 3.0 | 0.4 | -5.9 | 4.6 |
Vaccitech plc (VACC) Company Bio
Vaccitech plc is a clinical-stage biopharmaceutical company that engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. Its therapeutic programs include VTP-300, indicated for the treatment of chronic hepatitis B infection; VTP-200, indicated for the treatment of human papilloma virus infection; VTP-850, indicated for the treatment of prostate cancer; and VTP-600, indicated for the treatment of non-small cell lung cancer. The company's prophylactic programs include VTP-400 for the prevention of herpes zoster or shingles; and VTP-500 for the prevention of Middle East respiratory syndrome. In addition, it is developing AZD1222, a COVID-19 vaccine. Vaccitech plc was formerly known as Vaccitech Rx Limited and changed its name to Vaccitech plc on March 31, 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, United Kingdom.
Latest VACC News From Around the Web
Below are the latest news stories about VACCITECH PLC that investors may wish to consider to help them evaluate VACC as an investment opportunity.
Newsflash: Vaccitech plc (NASDAQ:VACC) Analysts Have Been Trimming Their Revenue ForecastsMarket forces rained on the parade of Vaccitech plc ( NASDAQ:VACC ) shareholders today, when the analysts downgraded... |
Vaccitech Reports First Quarter 2023 Financial Results and Recent Corporate DevelopmentsOXFORD, United Kingdom, May 12, 2023 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC) (the Company, we or us), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases, autoimmunity and cancer, today announced its financial results for the first quarter of 2023 and an overview of the Company’s progress. “2023 has kicked off strongly for Vaccitech. In the first quarter, we s |
Revenues Working Against Vaccitech plc's (NASDAQ:VACC) Share PriceVaccitech plc's ( NASDAQ:VACC ) price-to-sales (or "P/S") ratio of 2x might make it look like a strong buy right now... |
Vaccitech Presents Interim Data from Phase 1b/2 Study of VTP-200 at 35th Annual International Papillomavirus Conference (IPVC) Highlighting Favorable Tolerability and Immunogenicity ProfileVTP-200 was generally well-tolerated and was administered with no product-related grade 3 unsolicited adverse events and no product-related serious adverse events (SAEs) in women with low grade human papillomavirus-related cervical lesionsInterim data showed encouraging initial immunogenicity results, particularly in relation to the E1, E2 and E6 antigens OXFORD, United Kingdom, April 17, 2023 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company focused on |
7 Thrilling Biotech Stocks for Aggressive Investors to BuyAmid the noise of the global markets recently, these speculative biotech stocks to buy might trade with a mind of their own. |
VACC Price Returns
| 1-mo | -2.94% |
| 3-mo | -23.00% |
| 6-mo | -1.49% |
| 1-year | -48.67% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -1.70% |
| 2022 | -78.85% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...